Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-824X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage ; volume:6 ; number:1 ; day:6 ; month:9 ; year:2014 ; pages:1-13 ; date:12.2014
Vascular cell ; 6, Heft 1 (6.9.2014), 1-13, 12.2014
- Creator
-
Yamamoto, Yuji
Matsui, Junji
Matsushima, Tomohiro
Obaishi, Hiroshi
Miyazaki, Kazuki
Nakamura, Katsuji
Tohyama, Osamu
Semba, Taro
Yamaguchi, Atsumi
Hoshi, Sachi Suzuki
Mimura, Fusayo
Haneda, Toru
Fukuda, Yoshio
Kamata, Jun-ichi
Takahashi, Keiko
Matsukura, Masayuki
Wakabayashi, Toshiaki
Asada, Makoto
Nomoto, Ken-ichi
Watanabe, Tatsuo
Dezso, Zoltan
Yoshimatsu, Kentaro
Funahashi, Yasuhiro
Tsuruoka, Akihiko
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/2045-824X-6-18
- URN
-
urn:nbn:de:101:1-2021082121441772013789
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Yamamoto, Yuji
- Matsui, Junji
- Matsushima, Tomohiro
- Obaishi, Hiroshi
- Miyazaki, Kazuki
- Nakamura, Katsuji
- Tohyama, Osamu
- Semba, Taro
- Yamaguchi, Atsumi
- Hoshi, Sachi Suzuki
- Mimura, Fusayo
- Haneda, Toru
- Fukuda, Yoshio
- Kamata, Jun-ichi
- Takahashi, Keiko
- Matsukura, Masayuki
- Wakabayashi, Toshiaki
- Asada, Makoto
- Nomoto, Ken-ichi
- Watanabe, Tatsuo
- Dezso, Zoltan
- Yoshimatsu, Kentaro
- Funahashi, Yasuhiro
- Tsuruoka, Akihiko
- SpringerLink (Online service)
Other Objects (12)
Inhibition von FGFR, PDGFR und VEGFR hemmt Tumorwachstum, Angiogenese und Metastasierung des Pankreaskarzinoms in einem experimentellen Modell
Inhibition von FGFR, PDGFR und VEGFR hemmt Tumorwachstum, Angiogenese und Metastasierung des Pankreaskarzinoms in einem experimentellen Modell
Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
Identification of a Selective FLT3 Inhibitor with Low Activity against VEGFR, FGFR, PDGFR, c‐KIT, and RET Anti‐Targets
Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors
Targeting FGFR for cancer therapy
Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma
Lenvatinib (Kisplyx) : Lenvatinib in Kombination mit Everolismus beim fortgeschrittenen Nierenzellkarzinom mit Hirnmetastasen
Angiogenese und Wachstum des C6-Glioms : Konsequenzen einer selektiven Ablation der Signaltransduktionswege von VEGF-VEGFR-2, FGF_FGFR-1 und PDGF-PDGFR-β ; eine intravitalmikroskopische Studie
FGFR-gerichtete Therapie von Kopf-Hals-Karzinomen
Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
Hyperacute xenograft rejection
Inhibition von FGFR, PDGFR und VEGFR hemmt Tumorwachstum, Angiogenese und Metastasierung des Pankreaskarzinoms in einem experimentellen Modell
Inhibition von FGFR, PDGFR und VEGFR hemmt Tumorwachstum, Angiogenese und Metastasierung des Pankreaskarzinoms in einem experimentellen Modell
Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
Identification of a Selective FLT3 Inhibitor with Low Activity against VEGFR, FGFR, PDGFR, c‐KIT, and RET Anti‐Targets
Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors
Targeting FGFR for cancer therapy
Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma
Lenvatinib (Kisplyx) : Lenvatinib in Kombination mit Everolismus beim fortgeschrittenen Nierenzellkarzinom mit Hirnmetastasen
Angiogenese und Wachstum des C6-Glioms : Konsequenzen einer selektiven Ablation der Signaltransduktionswege von VEGF-VEGFR-2, FGF_FGFR-1 und PDGF-PDGFR-β ; eine intravitalmikroskopische Studie
FGFR-gerichtete Therapie von Kopf-Hals-Karzinomen
Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment
Hyperacute xenograft rejection
Inhibition von FGFR, PDGFR und VEGFR hemmt Tumorwachstum, Angiogenese und Metastasierung des Pankreaskarzinoms in einem experimentellen Modell
Inhibition von FGFR, PDGFR und VEGFR hemmt Tumorwachstum, Angiogenese und Metastasierung des Pankreaskarzinoms in einem experimentellen Modell
Dual FGFR and VEGFR inhibition synergistically restrain hexokinase 2-dependent lymphangiogenesis and immune escape in intrahepatic cholangiocarcinoma
Identification of a Selective FLT3 Inhibitor with Low Activity against VEGFR, FGFR, PDGFR, c‐KIT, and RET Anti‐Targets
Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors
Targeting FGFR for cancer therapy
Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma
Lenvatinib (Kisplyx) : Lenvatinib in Kombination mit Everolismus beim fortgeschrittenen Nierenzellkarzinom mit Hirnmetastasen
Angiogenese und Wachstum des C6-Glioms : Konsequenzen einer selektiven Ablation der Signaltransduktionswege von VEGF-VEGFR-2, FGF_FGFR-1 und PDGF-PDGFR-β ; eine intravitalmikroskopische Studie
FGFR-gerichtete Therapie von Kopf-Hals-Karzinomen
Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment